In support of this notion, 5′-Aza as a single agent and particularly in combination with either ivosidenib (IDH inhibitor) or venetoclax (BCL2 apoptosis regulator inhibitor) has efficacy in IDH-mutated AML (47, 48). This evidence concerns the gene BCL2 and acute myeloid leukemia.